S&P 500   3,845.08
DOW   31,037.68
QQQ   288.80
S&P 500   3,845.08
DOW   31,037.68
QQQ   288.80
S&P 500   3,845.08
DOW   31,037.68
QQQ   288.80
S&P 500   3,845.08
DOW   31,037.68
QQQ   288.80

Orchard Therapeutics Stock Forecast, Price & News

+0.03 (+4.65%)
(As of 07/6/2022 12:00 AM ET)
Today's Range
50-Day Range
52-Week Range
1.92 million shs
Average Volume
1.24 million shs
Market Capitalization
$84.92 million
P/E Ratio
Dividend Yield
Price Target

Orchard Therapeutics MarketRank™ Forecast

Analyst Rating
2.33 Rating Score
1,049.0% Upside
$7.75 Price Target
Short Interest
1.13% of Float Sold Short
Dividend Strength
News Sentiment
0.22mentions of Orchard Therapeutics in the last 14 days
Based on 9 Articles This Week
Insider Trading
Proj. Earnings Growth
From ($0.95) to ($0.75) Per Share

Overall MarketRank

MarketRank is calculated as 30% analysis score, 20% valuation score, 10% short interest score, 10% dividend score, 10% sustainability score, 10% news and social score, and 10% insider trading score.

1.64 out of 5 stars

Medical Sector

884th out of 1,433 stocks

Biological Products, Except Diagnostic Industry

146th out of 220 stocks

30 days | 90 days | 365 days | Advanced Chart

Receive ORTX Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Orchard Therapeutics and its competitors with MarketBeat's FREE daily newsletter.

Orchard Therapeutics logo

About Orchard Therapeutics (NASDAQ:ORTX) Stock

Orchard Therapeutics plc, a biopharmaceutical company, develops gene therapies for serious and life-threatening rare diseases in the United Kingdom, European Union, and the United States. The company's gene therapy approach seeks to transform a patient's hematopoietic stem cells into a gene-modified cellular drug product to treat the patient's disease through a single administration. It provides Strimvelis, a gammaretroviral-based product for the treatment of adenosine deaminase-severe combined immunodeficiency (ADA-SCID). The company's clinical development products comprise OTL-101 for the treatment of ADA-SCID; OTL-200 to treat metachromatic leukodystrophy; OTL-103 for the treatment of Wiskott-Aldrich syndrome; OTL-102 for X-linked chronic granulomatous disease; and OTL-300 for transfusion-dependent beta-thalassemia. Its preclinical programs include OTL-203 for mucopolysaccharidosis type I, OTL-201 for mucopolysaccharidosis type MPS-IIIA, and OTL-202 for mucopolysaccharidosis type IIIB. It has a strategic collaboration agreement with Pharming Group N.V. for research, development, manufacturing, and commercialization of OTL-105, an investigational ex vivo autologous hematopoietic stem cell gene therapy for the treatment of hereditary angioedema. The company was formerly known as Orchard Rx Limited. Orchard Therapeutics plc was founded in 2015 and is headquartered in London, the United Kingdom.

ORTX Stock News Headlines

Big Potential Stock For 2022
This hot penny stock is on the move. Put it on your radar now.
Big Potential Stock For 2022
This hot penny stock is on the move. Put it on your radar now.
Tourists return to Old Orchard Beach
See More Headlines

Industry, Sector and Symbol

Biological products, except diagnostic
Current Symbol
Year Founded

Company Calendar

Last Earnings
Next Earnings (Estimated)
Fiscal Year End

Price Target and Rating

Average Stock Price Forecast
High Stock Price Forecast
Low Stock Price Forecast
Forecasted Upside/Downside
Consensus Rating
Rating Score (0-4)
Research Coverage
6 Analysts


Net Income
Pretax Margin


Sales & Book Value

Annual Sales
$1.67 million
Book Value
$1.67 per share


Free Float
Market Cap
$84.92 million
Not Optionable

Orchard Therapeutics Frequently Asked Questions

Should I buy or sell Orchard Therapeutics stock right now?

6 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Orchard Therapeutics in the last twelve months. There are currently 1 sell rating, 2 hold ratings and 3 buy ratings for the stock. The consensus among Wall Street analysts is that investors should "hold" Orchard Therapeutics stock. A hold rating indicates that analysts believe investors should maintain any existing positions they have in ORTX, but not buy additional shares or sell existing shares.
View analyst ratings for Orchard Therapeutics
or view top-rated stocks.

What is Orchard Therapeutics' stock price forecast for 2022?

6 brokerages have issued 1-year target prices for Orchard Therapeutics' stock. Their ORTX stock forecasts range from $4.00 to $13.00. On average, they expect Orchard Therapeutics' stock price to reach $7.75 in the next twelve months. This suggests a possible upside of 1,049.0% from the stock's current price.
View analysts' price targets for Orchard Therapeutics
or view top-rated stocks among Wall Street analysts.

How has Orchard Therapeutics' stock price performed in 2022?

Orchard Therapeutics' stock was trading at $1.32 at the start of the year. Since then, ORTX stock has decreased by 48.9% and is now trading at $0.6745.
View the best growth stocks for 2022 here

When is Orchard Therapeutics' next earnings date?

Orchard Therapeutics is scheduled to release its next quarterly earnings announcement on Wednesday, August 3rd 2022.
View our earnings forecast for Orchard Therapeutics

How were Orchard Therapeutics' earnings last quarter?

Orchard Therapeutics plc (NASDAQ:ORTX) announced its quarterly earnings results on Thursday, May, 12th. The company reported ($0.35) EPS for the quarter, missing analysts' consensus estimates of ($0.25) by $0.10. The company earned $5.52 million during the quarter, compared to the consensus estimate of $4.97 million.
View Orchard Therapeutics' earnings history

Who are Orchard Therapeutics' key executives?

Orchard Therapeutics' management team includes the following people:
  • Dr. Bobby Gaspar M.D., Ph.D., CEO, Member of Scientific Advisory Board & Exec. Director (Age 58, Pay $850.18k)
  • Mr. Frank E. Thomas, Pres & COO (Age 52, Pay $716.6k)
  • Dr. Nicoletta Loggia Ph.D., Chief Technical Officer
  • Dr. Fulvio Mavilio Ph.D., Chief Scientific Officer
  • Ms. Renee T. Leck, Director of Investor Relations
  • Benjamin Navon, Director of Corp. Communications
  • Mr. John Cerio, Chief Human Resource Officer
  • Dr. Anne Dupraz-Poiseau, Chief Devel. Officer
  • Mr. Robin Kenselaar, Sr. VP & GM of EMEA Commercial Operations
  • Mr. Braden Parker, Chief Commercial Officer

What other stocks do shareholders of Orchard Therapeutics own?

Based on aggregate information from My MarketBeat watchlists, some companies that other Orchard Therapeutics investors own include Sorrento Therapeutics (SRNE), SCYNEXIS (SCYX), Matinas BioPharma (MTNB), Viking Therapeutics (VKTX), Allena Pharmaceuticals (ALNA), Corbus Pharmaceuticals (CRBP), Entasis Therapeutics (ETTX), (NGM), Selecta Biosciences (SELB) and VBI Vaccines (VBIV).

When did Orchard Therapeutics IPO?

(ORTX) raised $200 million in an initial public offering on Wednesday, October 31st 2018. The company issued 13,300,000 shares at $14.00-$16.00 per share. J.P. Morgan, Goldman Sachs and Cowen served as the underwriters for the IPO and Wedbush PacGrow was co-manager.

What is Orchard Therapeutics' stock symbol?

Orchard Therapeutics trades on the NASDAQ under the ticker symbol "ORTX."

How do I buy shares of Orchard Therapeutics?

Shares of ORTX can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.

What is Orchard Therapeutics' stock price today?

One share of ORTX stock can currently be purchased for approximately $0.67.

How much money does Orchard Therapeutics make?

Orchard Therapeutics (NASDAQ:ORTX) has a market capitalization of $84.92 million and generates $1.67 million in revenue each year. The company earns $-144,580,000.00 in net income (profit) each year or ($1.22) on an earnings per share basis.

How many employees does Orchard Therapeutics have?

Orchard Therapeutics employs 259 workers across the globe.

How can I contact Orchard Therapeutics?

Orchard Therapeutics' mailing address is 108 CANNON STREET, LONDON X0, EC4N 6EU. The official website for Orchard Therapeutics is www.orchard-tx.com. The company can be reached via phone at 442038088286.

This page (NASDAQ:ORTX) was last updated on 7/7/2022 by MarketBeat.com Staff

MarketBeat Resources

Premium Research Tools

MarketBeat All Access subscribers can access stock screeners, the Idea Engine, data export tools, research reports, and other premium tools.

Discover All Access

Market Data and Calendars

Looking for new stock ideas? Want to see which stocks are moving? View our full suite of financial calendars and market data tables, all for free.

View Market Data

Investing Education and Resources

Receive a free world-class investing education from MarketBeat. Learn about financial terms, types of investments, trading strategies and more.

Financial Terms
Details Here
MarketBeat - Stock Market News and Research Tools logo

MarketBeat empowers individual investors to make better trading decisions by providing real-time financial data and objective market analysis. Whether you’re looking for analyst ratings, corporate buybacks, dividends, earnings, economic reports, financials, insider trades, IPOs, SEC filings or stock splits, MarketBeat has the objective information you need to analyze any stock. Learn more about MarketBeat.

MarketBeat is accredited by the Better Business Bureau MarketBeat is rated as Great on TrustPilot

© American Consumer News, LLC dba MarketBeat® 2010-2022. All rights reserved.
326 E 8th St #105, Sioux Falls, SD 57103 | U.S. Based Support Team at contact@marketbeat.com | (844) 978-6257
MarketBeat does not provide personalized financial advice and does not issue recommendations or offers to buy stock or sell any security.

Our Accessibility Statement | Terms of Service | Do Not Sell My Information | RSS Feeds

© 2022 Market data provided is at least 10-minutes delayed and hosted by Barchart Solutions. Information is provided 'as-is' and solely for informational purposes, not for trading purposes or advice, and is delayed. To see all exchange delays and terms of use please see disclaimer.